Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
$630K | -$0.06 | -- | -67.39% | $8.75 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
$2.18 | $8.75 | $146.4M | -- | $0.00 | 0% | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8150 | $12.3077 | $209.3M | -- | $0.00 | 0% | 190.87x |
|
PMI
Picard Medical
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VNRX
VolitionRX Ltd.
|
$0.25 | $2.20 | $31.3M | -- | $0.00 | 0% | 17.45x |
|
VTAK
Catheter Precision, Inc.
|
$1.81 | -- | $2.2M | 0.40x | $0.00 | 0% | 8.51x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $109.2M | 76.47x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
1.14% | -0.800 | 0.45% | 27.34x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
PMI
Picard Medical
|
-- | 0.000 | -- | -- |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-$10K | -$3.9M | -44.68% | -45.11% | -- | -$3.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Perspective Therapeutics, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -12425.36%. Microbot Medical, Inc.'s return on equity of -45.11% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -$0.07 | $79.1M |
|
CATX
Perspective Therapeutics, Inc.
|
-270.81% | -$0.35 | $245.5M |
Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 301.38%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than Microbot Medical, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Microbot Medical, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
2 | 0 | 0 |
|
CATX
Perspective Therapeutics, Inc.
|
12 | 1 | 0 |
Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
Microbot Medical, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Microbot Medical, Inc.'s net income of -$3.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -- | -- | -$3.6M |
|
CATX
Perspective Therapeutics, Inc.
|
190.87x | -- | $209K | -$26M |
Picard Medical has a net margin of -- compared to Microbot Medical, Inc.'s net margin of --. Microbot Medical, Inc.'s return on equity of -45.11% beat Picard Medical's return on equity of --.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -$0.07 | $79.1M |
|
PMI
Picard Medical
|
-- | -- | -- |
Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 301.38%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Microbot Medical, Inc. has higher upside potential than Picard Medical, analysts believe Microbot Medical, Inc. is more attractive than Picard Medical.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
2 | 0 | 0 |
|
PMI
Picard Medical
|
0 | 0 | 0 |
Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.
Microbot Medical, Inc. quarterly revenues are --, which are larger than Picard Medical quarterly revenues of --. Microbot Medical, Inc.'s net income of -$3.6M is higher than Picard Medical's net income of --. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -- | -- | -$3.6M |
|
PMI
Picard Medical
|
-- | -- | -- | -- |
VolitionRX Ltd. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -862.39%. Microbot Medical, Inc.'s return on equity of -45.11% beat VolitionRX Ltd.'s return on equity of --.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -$0.07 | $79.1M |
|
VNRX
VolitionRX Ltd.
|
50.73% | -$0.05 | -$24.7M |
Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 301.38%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 763.76%. Given that VolitionRX Ltd. has higher upside potential than Microbot Medical, Inc., analysts believe VolitionRX Ltd. is more attractive than Microbot Medical, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
2 | 0 | 0 |
|
VNRX
VolitionRX Ltd.
|
4 | 2 | 0 |
Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
Microbot Medical, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Microbot Medical, Inc.'s net income of -$3.6M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 17.45x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -- | -- | -$3.6M |
|
VNRX
VolitionRX Ltd.
|
17.45x | -- | $627.3K | -$5.4M |
Catheter Precision, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -1037.17%. Microbot Medical, Inc.'s return on equity of -45.11% beat Catheter Precision, Inc.'s return on equity of -192.05%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -$0.07 | $79.1M |
|
VTAK
Catheter Precision, Inc.
|
-141.59% | -$1.70 | $21.3M |
Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 301.38%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1999.51%. Given that Catheter Precision, Inc. has higher upside potential than Microbot Medical, Inc., analysts believe Catheter Precision, Inc. is more attractive than Microbot Medical, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
2 | 0 | 0 |
|
VTAK
Catheter Precision, Inc.
|
0 | 0 | 0 |
Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
Microbot Medical, Inc. quarterly revenues are --, which are smaller than Catheter Precision, Inc. quarterly revenues of $226K. Microbot Medical, Inc.'s net income of -$3.6M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 8.51x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -- | -- | -$3.6M |
|
VTAK
Catheter Precision, Inc.
|
8.51x | 0.40x | $226K | -$2.3M |
Xtant Medical Holdings, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of 3.93%. Microbot Medical, Inc.'s return on equity of -45.11% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -$0.07 | $79.1M |
|
XTNT
Xtant Medical Holdings, Inc.
|
66.13% | $0.01 | $82.9M |
Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 301.38%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.31%. Given that Microbot Medical, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Microbot Medical, Inc. is more attractive than Xtant Medical Holdings, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
2 | 0 | 0 |
|
XTNT
Xtant Medical Holdings, Inc.
|
2 | 0 | 0 |
Microbot Medical, Inc. has a beta of 1.171, which suggesting that the stock is 17.1% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
Microbot Medical, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Microbot Medical, Inc.'s net income of -$3.6M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
MBOT
Microbot Medical, Inc.
|
-- | -- | -- | -$3.6M |
|
XTNT
Xtant Medical Holdings, Inc.
|
0.85x | 76.47x | $33.3M | $1.3M |
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.